168 related articles for article (PubMed ID: 31205561)
1. EZH2/Bcl-2 Coexpression Predicts Worse Survival in Diffuse Large B-cell Lymphomas and Demonstrates Poor Efficacy to Rituximab in Localized Lesions.
Deng Y; Chen X; Huang C; Chen G; Chen F; Lu J; Shi X; He C; Zeng Z; Qiu Y; Chen J; Lin R; Chen Y; Chen J
J Cancer; 2019; 10(9):2006-2017. PubMed ID: 31205561
[TBL] [Abstract][Full Text] [Related]
2. [Significance of H3K27me3 and EZH2 in Predicting the Therapeutic Efficacy of Diffuse Large B-Cell Lymphoma].
Deng YJ; Chen G; Zhu WF; Chen XH; Hong HL; Huang LM; Shi X; Chen JM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):159-165. PubMed ID: 29397836
[TBL] [Abstract][Full Text] [Related]
3. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of the Predictive Value of EZH2 Expression Level on the Clinical Efficacy and Long-term Prognosis of Patients with Primary Gastrointestinal Diffuse Large B-cell Lymphoma].
Lin JY; Zheng YB; He HM; Wang JS; Yang Y; Chen DG; Zou SP; Wang C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):725-730. PubMed ID: 34105464
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological Features, Treatment, and Prognosis in Primary Diffuse Large B Cell Lymphoma of the Breast: A Retrospective Study of 46 Patients.
Luo H; Yi P; Wang W; Li K; Meng L; Li J; Zeng W; Tang M
Med Sci Monit; 2019 Nov; 25():8671-8682. PubMed ID: 31734687
[TBL] [Abstract][Full Text] [Related]
6. A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma.
Oñate-Ocaña LF; Ponce-Martínez M; Taja-Chayeb L; Gutiérrez-Hernández O; Avilés-Salas A; Cantú-de-León D; Dueñas-González A; Candelaria-Hernández M
Rev Invest Clin; 2021 Nov; 73(6):362-370. PubMed ID: 34044429
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Histone Modifying Enzyme EZH2 in RCHOP-Treated Diffuse Large B-Cell Lymphoma and High Grade B-Cell Lymphoma.
Petronilho S; Sequeira JP; Paulino S; Lopes P; Lisboa S; Chacim S; Lobo J; Teixeira M; Jerónimo C; Henrique R
J Pers Med; 2021 Dec; 11(12):. PubMed ID: 34945856
[TBL] [Abstract][Full Text] [Related]
8. Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wong KK; Ch'ng ES; Loo SK; Husin A; Muruzabal MA; Møller MB; Pedersen LM; Pomposo MP; Gaafar A; Banham AH; Green TM; Lawrie CH
Exp Mol Pathol; 2015 Dec; 99(3):537-45. PubMed ID: 26341140
[TBL] [Abstract][Full Text] [Related]
9. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
10. [Expression and Clinical Significance of EZH2 in Patients with Diffuse Large B Cell Lymphoma Accompanied by HBV Infection].
Zhang YT; Feng D; Wang Y; Li DP; Li ZY; Qiu TT; Xu KL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):855-860. PubMed ID: 32552947
[TBL] [Abstract][Full Text] [Related]
11. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
[TBL] [Abstract][Full Text] [Related]
12. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Meng B; Zhang H
Hematol Oncol; 2019 Oct; 37(4):360-367. PubMed ID: 31359442
[TBL] [Abstract][Full Text] [Related]
13. TRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma.
Loo SK; Ch'ng ES; Md Salleh MS; Banham AH; Pedersen LM; Møller MB; Green TM; Wong KK
Histopathology; 2017 Jul; 71(1):98-111. PubMed ID: 28248435
[TBL] [Abstract][Full Text] [Related]
14. High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.
Okina S; Yanagisawa N; Yokoyama M; Sakurai Y; Numata Y; Umezawa A; Higashihara M; Murakumo Y
Int J Hematol; 2015 Dec; 102(6):662-9. PubMed ID: 26449786
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
[No Abstract] [Full Text] [Related]
16. [Effect of Different Protein Expression and Clinical Features on the Prognosis of Patients with Diffuse Large B-Cell Lymphoma].
Cheng FF; Chen JF; Yang LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1490-1496. PubMed ID: 31607303
[TBL] [Abstract][Full Text] [Related]
17. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
[TBL] [Abstract][Full Text] [Related]
18. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
[TBL] [Abstract][Full Text] [Related]
19. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]